C. Davis

发表

Prediction of animal clearance using naïve Bayesian classification and extended connectivity fingerprints

T. A. McIntyre, C. Han, C. Davis, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

A population pharmacokinetic‐pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

D. Mould, C. Davis, M. Elliott, 1999, Clinical pharmacology and therapeutics.

Differences in Effects on Myocardium and Mitochondria by Angiogenic Inhibitors Suggest Separate Mechanisms of Cardiotoxicity

R. Coatney, C. Davis, Kendall S. Frazier, 2010, Toxicologic pathology.

Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.

C. Davis, D. Holt, I. Macphee, 2000, Kidney international.

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers.

C. Davis, D. Jorkasky, K. Thompson, 1996, The Journal of infectious diseases.

Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice.

C. Davis, T. Hart, T. Sellers, 2001, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.

C. Davis, E. Minthorn, L. Benincosa, 1999, The Journal of pharmacology and experimental therapeutics.

Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.

C. Davis, B. K. Park, Peter D Gibbons, 2009, Journal of medicinal chemistry.

Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors.

J. F. Mack, J. Luengo, Ramona N Plant, 2012, ACS medicinal chemistry letters.

Pharmacokinetics of the bovine formulation of enrofloxacin (Baytril 100) in horses.

C. Davis, D. Boothe, S. Wilkie, 2001, Veterinary therapeutics : research in applied veterinary medicine.

Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.

C. Davis, G. Rhodes, T. Hart, 1995, Drug metabolism and disposition: the biological fate of chemicals.

Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials.

C. Davis, A. Shone, S. Ward, 2009, Journal of Pharmacy and Science.

Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.

W J Jusko, W. Jusko, C. Davis, 2000, The Journal of pharmacology and experimental therapeutics.

Involvement of Intestinal Uptake Transporters in the Absorption of Azithromycin and Clarithromycin in the Rat

P. Dawson, C. Davis, Anuradha Rao, 2008, Drug Metabolism and Disposition.

Subcutaneous bioavailability of a PRIMATIZED IgG1 anti-human CD4 monoclonal antibody is dose dependent in transgenic mice bearing human CD4.

C. Davis, P. Bugelski, 1998, Drug delivery.

Pharmacokinetics and Brain Penetration of Casopitant, a Potent and Selective Neurokinin-1 Receptor Antagonist, in the Ferret

C. Davis, D. Rominger, A. Shu, 2008, Drug Metabolism and Disposition.

PHARMACOKINETICS AND BRAIN PENETRATION OF CASOPITANT, A POTENT AND SELECTIVE NK-1 RECEPTOR ANTAGONIST, IN THE FERRET

C. Davis, A. Shu, E. Minthorn, 2008 .

Interaction of Macrolide Antibiotics with Intestinally Expressed Human and Rat Organic Anion-Transporting Polypeptides

P. Dawson, C. Davis, Anuradha Rao, 2009, Drug Metabolism and Disposition.

Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency‐Guided First‐in‐Human Studies

M. Goldstein, B. Weber, C. Davis, 2020, Clinical and translational science.

Pharmacokinetic and pharmacodynamic modeling of humanized anti–factor IX antibody (SB 249417) in humans

W. Jusko, C. Davis, E. Minthorn, 2002, Clinical pharmacology and therapeutics.

Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.

S. Parapini, D. Taramelli, C. Davis, 2009, Journal of medicinal chemistry.

Disposition of growth hormone-releasing peptide (SK&F 110679) in rat and dog following intravenous or subcutaneous administration.

C. Davis, G. Rhodes, C. Crysler, 1994, Drug Metabolism And Disposition.

Transdermal iontophoretic delivery of [3H]GHRP in rats

Hung‐Yuan Cheng, C. Davis, H. Ellens, 1997 .

Differences in the total body clearance of lead compounds in the rat and mouse: Impact on pharmacokinetic screening strategy

T. A. McIntyre, C. Han, C. Davis, 2008 .

Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.

C. Davis, M. Totoritis, T. Hepburn, 2003, Rheumatology.

CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.

Michael Weisman, F. Breedveld, M. Weisman, 2002, The Journal of rheumatology.

Pharmacokinetics of LEE011, a CDK4/6 Inhibitor, in Adult and Pediatric Patients With Advanced Tumors

C. Davis, A. Chakraborty, A. Matano, 2014 .

Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4.

C. Davis, T. Hart, D. Herzyk, 2000, The Journal of pharmacology and experimental therapeutics.

Accumulation of Antibody-Target Complexes and the Pharmacodynamics of Clotting after Single Intravenous Administration of Humanized Anti-Factor IX Monoclonal Antibody to Rats

W. Jusko, C. Davis, L. Benincosa, 1999 .

Disposition of metabolically labeled recombinant soluble CD4 (sT4) in male Sprague-Dawley rats following intravenous and subcutaneous administration.

C. Davis, K. Boyle, K. Fong, 1992, Drug metabolism and disposition: the biological fate of chemicals.

Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor.

C. Davis, S. Ferrer, D. Gargallo, 2006, Journal of pharmaceutical sciences.

Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials.

C. Davis, A. Shone, S. Ward, 2009, Journal of pharmaceutical sciences.